Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy.
about
Recommendations for the pharmacological management of neuropathic pain: an overview and literature updatePain and Poppies: The Good, the Bad, and the Ugly of Opioid AnalgesicsHigh-affinity glutamate transporters in chronic pain: an emerging therapeutic targetThe Relationship between Dyslipidemia and Acute Axonal Function in Type 2 Diabetes Mellitus In VivoBehavioral indices of ongoing pain are largely unchanged in male mice with tissue or nerve injury-induced mechanical hypersensitivityGuidelines in the management of diabetic nerve pain: clinical utility of pregabalin.Prevalence of neuropathic pain after radical sacral chordoma resection: an observational cohort study with 10-year follow-up.Does Neuropathic Pain Affect the Quality of Sleep?The effect of Neuragen PN on neuropathic pain: A randomized, double blind, placebo controlled clinical trialNeuroinflammation-a co-occurring phenomenon linking chronic pain and opioid dependence.A preliminary report on stem cell therapy for neuropathic pain in humans.Quality improvement in neurology: Distal symmetric polyneuropathy quality measuresTreatment considerations for elderly and frail patients with neuropathic painHow close are we in utilizing functional neuroimaging in routine clinical diagnosis of neuropathic pain?Characteristics of neuropathic pain in patients with spinal cord injury.Increased methylation of the MOR gene proximal promoter in primary sensory neurons plays a crucial role in the decreased analgesic effect of opioids in neuropathic pain.Therapy using implanted organic bioelectronics.Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis.Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life.Nerve injury-induced epigenetic silencing of opioid receptors controlled by DNMT3a in primary afferent neurons.Pregabalin versus gabapentin in the management of peripheral neuropathic pain associated with post-herpetic neuralgia and diabetic neuropathy: a cost effectiveness analysis for the Greek healthcare setting.Treatment of localized neuropathic pain of different etiologies with the 5% lidocaine medicated plaster - a case series.Validity and reliability of the Japanese version of the painDETECT questionnaire: a multicenter observational study.Dynamic temporal and spatial regulation of mu opioid receptor expression in primary afferent neurons following spinal nerve injury.Neuropathic pain: a personal case reflection on a critical incident.Double-blind, placebo-controlled study of HGF gene therapy in diabetic neuropathy.Association between extracellular signal-regulated kinase expression and the anti-allodynic effect in rats with spared nerve injury by applying immediate pulsed radiofrequency.Behavior of neuropathic pain in mice following chronic constriction injury comparing silk and catgut ligatures.What we know about primary dysmenorrhea today: a critical review.Psychometric Validation of the Japanese Version of the Neuropathic Pain Symptom Inventory.Brain stimulation in the treatment of chronic neuropathic and non-cancerous pain.Cross-cultural Adaptation and Linguistic Validation of the Korean Version of the Leeds Assessment of Neuropathic Symptoms and Signs Pain Scale.Differential effects of peripheral versus central coadministration of QX-314 and capsaicin on neuropathic pain in ratsTreatment of localized neuropathic pain after disk herniation with 5% lidocaine medicated plaster.Surgically induced neuropathic pain: understanding the perioperative processCapsaicin 8% patch versus oral pregabalin in patients with peripheral neuropathic pain.Burden of illness associated with painful diabetic peripheral neuropathy among adults seeking treatment in the US: results from a retrospective chart review and cross-sectional surveyAre treatment benefits in neuropathic pain reflected in the Self Assessment of Treatment questionnaire?Can treatment success with 5% lidocaine medicated plaster be predicted in cancer pain with neuropathic components or trigeminal neuropathic pain?Effects of axonal ion channel dysfunction on quality of life in type 2 diabetes
P2860
Q24616897-D290FC1E-C132-49E9-BBD4-2B2C0F2D21BDQ26782928-7C670F2A-C1AD-4862-9E67-C7E098E77F74Q27020953-9A9EA57F-7175-462D-936D-1FD474DAB43BQ28551366-0CE1CB0F-BD52-45AA-8632-7D73FF93E341Q30499740-ECB5730D-46F7-4517-9308-B0E0535E0F31Q30537158-95D2C9A1-CA16-4B03-860D-0DDBD07BF32DQ33275388-EC3B1906-385E-4704-B597-F9D33618AC22Q33557425-AE0984E8-12CB-4B0D-A57D-4132F43D4A60Q33582828-74050468-51D0-4169-92D5-70372F245495Q33602197-487E956C-5398-4CD1-B98C-848F5B05219DQ33610446-6E4C5145-FB14-485A-8E8B-25FABFF84723Q33654631-39492239-F11F-455F-AE29-4C943AD184EEQ33747265-BBC77843-B477-406D-A651-317BFD916041Q33835945-4539E6A7-D363-4660-A44B-8FC2EC0938FBQ33882897-10A03D71-568E-4A29-A2F5-82C98DB93865Q34062512-A10D86A5-46DA-4008-A8B4-1D57CD704067Q34502830-9FDB5806-877C-48FC-8477-EE9B28E90460Q34640959-3AA05A8D-02CB-4278-9445-3DF12CEE015FQ34642760-C6056D48-A0A9-4D70-B1F6-52EF43A618F6Q34680966-648CCDCD-8098-4931-B88E-CCAF7B77AAA4Q34753719-AC501723-EEBC-4190-89EF-0A6150D1AF33Q34783788-554FCDE4-73F9-4087-9B28-34815F8B8C6AQ35009803-25527930-9D58-4F61-8B32-14E10AA5B221Q35085646-86FB3310-C65B-4C7C-AFD2-528BE7856C62Q35245083-85CCDEDB-83C3-48FE-8542-CF44B73C2007Q35619182-41E6B745-01A4-4515-87A7-C9DDFC9AEBAAQ35664562-5F76B5EC-B2C1-4316-BBDA-DA7CE98D7E5DQ35685947-BAB5C5BB-3BEF-4819-9E6E-4DC346FF9E55Q35766030-61D0D3C6-6507-4B5B-95A4-2418C4D8E147Q35850727-493C4454-E540-44F5-90DB-ECDE1103B990Q35947261-08C6BE99-3E0F-4EBF-863E-311303469494Q36007890-B75D1116-E3E8-404B-B127-F0852B390783Q36172356-653C0C75-D86F-4529-BECC-E3422CC3DCCDQ36196787-F504FB7A-14E6-4C20-B59D-2A2BB2EA9C02Q36536415-2A7C4BD4-03E1-4391-8F38-95E603D432FAQ36536768-FACCFB3B-F81E-4B93-A6B0-FA68AAEC64B2Q36600465-8F2AE340-A6BD-4CC3-B669-521B7C798421Q36687424-A167E5EF-9D28-472E-BA95-48B004AAE9B0Q36758278-209933CF-C73C-46AA-8BDE-E835CBBBBE4DQ36782662-1EBBDF83-EAF9-410B-A257-7E6468B06571
P2860
Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy.
@en
Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy.
@nl
type
label
Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy.
@en
Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy.
@nl
prefLabel
Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy.
@en
Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy.
@nl
P2860
P1433
P1476
Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy.
@en
P2860
P304
P356
10.2165/00019053-200927020-00002
P577
2009-01-01T00:00:00Z
P6179
1010122381